01PluriKit™
Cells, medium, and matrix. Designed to work together.
RTD® cells supplied with matched medium and matrix to simplify culture and minimize adaptation-related variability.
Explore PluriKit ↗Standardized iPSC starting materials for cell therapies and human cell models.
Low-passage, polyclonal cell lines. Prequalified high-density RTD® vials. Optimized, ready-to-use culture systems.
One cellular foundation.
Multiple paths to discovery and therapy.
Prequalified iPSC vials and complete, optimized cell culture systems, with dedicated routes for therapy development and human cell models.
01Cells, medium, and matrix. Designed to work together.
RTD® cells supplied with matched medium and matrix to simplify culture and minimize adaptation-related variability.
Explore PluriKit ↗
02Standardized. Prequalified. Ready to differentiate.
QC-tested, high-density cryopreserved cells that can eliminate approximately 10 days of conventional pre-differentiation expansion, depending on workflow.
Explore RTD iPSCs ↗
03Simplify the path from iPSCs to human cell models.
Integrated cell and reagent systems for reproducible iPSC culture, aggregate generation, and advanced research applications.
Explore PluriForm ↗High-density prequalified vials simplify your starting workflow. PluriKit extends that consistency with matched medium and matrix.
Find your iPSC solution ↗Rapid polyclonal reprogramming, engineered safety and immune evasion, and standardized ready-to-use formats are designed to work together.
Proprietary mRNA reprogramming rapidly generates low-passage, polyclonal iPSC populations, providing an advantageous starting material for downstream genetic engineering.
Explore reprogramming ↗FailSafe® provides a drug-inducible safety mechanism for unwanted proliferating cells. iACT provides immune-evasion engineering for allogeneic applications. Configurations vary by cell line.
RTD® cells are manufactured using standardized processes and QC-tested against defined specifications. Their high-density format reduces or eliminates pre-differentiation expansion.
View product formats ↗Low-passage starting cells reduce opportunities for culture-associated genetic changes. Standardized RTD® manufacturing and release testing help control variability. Performance remains line- and application-dependent.
The same quality-focused iPSC platform supports very different commercial applications.


More than a product catalog, we're a technical partner for development and adoption.
Explore development services ↗Generate patient- or donor-specific iPSCs using Pluristyx expertise.
Custom edits, clone selection, and engineered line development.
Analytical characterization, qualified cell banks, and manufacturing support.
Help customers establish suitable workflows around our products.

Make decisions with data, not just claims. Our team characterizes cell identity, viability, pluripotency, genetic stability, and performance in downstream workflows.
Explore the science ↗Protocols, publications, technical guidance, and application data in one place.
Product-specific workflows and handling guidance.
↗Research and scientific evidence from Pluristyx and collaborators.
↗Culture, characterization, and differentiation workflows.
↗Answers to common product and usage questions.
↓A sample of the planned technical FAQ area.
Ready-to-Differentiate® is Pluristyx's high-density cryopreserved iPSC format designed to reduce or eliminate pre-differentiation expansion. The appropriate workflow depends on the specific line and application.
Culture medium, matrix, and handling conditions affect cellular behavior. PluriKit packages compatible materials and instructions intended to support consistent growth and reduce adaptation-related variability.
No. Pluristyx offers unedited and engineered configurations. Available cell lines, engineering features, and licensing terms should be confirmed with the team.
Pluristyx commonly offers Limited Use License arrangements for evaluation, followed by separate commercial licensing discussions if the line fits the customer's program.
A practical path for selecting and adopting Pluristyx products and technologies.
Test candidate lines and systems under an appropriate Limited Use License, often over a 6–18 month evaluation period.
Select an unedited, FailSafe, or iACT + FailSafe configuration. Use product and custom development support as needed.
Discuss commercial licensing and establish supply of cell lines, RTD vials, and kits for ongoing programs.
Tell us about your cell line, culture system, or development requirements.